CDK4 and glioblastoma: Here, with the FDA-approved CDK4/6 inhibitor, palbociclib, we investigated the efficacy of blockade of Rb signaling against GBM and found out the role of PTEN in the potential of clinically applicable anti-CDK4/6 therapies.